文献速递间质性肺疾病

托珠单抗与利妥昔单抗治疗类风湿关节炎相关间质性肺病的比较效果:一项模拟目标试验

Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial.
PubMed 文献 · Chest · 2025-09-18

本研究利用TriNetX美国协作网络数据库,模拟目标试验比较托珠单抗与利妥昔单抗在类风湿关节炎相关间质性肺病(RA-ILD)患者中的预后。经倾向评分匹配后每组各1194例,5年全因死亡率无显著差异(HR 1.073,95%CI 0.881-1.305),住院和机械通气风险也相当。但在基线炎症标志物升高的患者中,托珠单抗的机械通气和全因死亡风险更高。

要点

  • 托珠单抗与利妥昔单抗在RA-ILD患者中5年全因死亡率无显著差异。
  • 基线炎症标志物升高的RA-ILD患者,托珠单抗机械通气和死亡风险更高。
  • TNF抑制剂初治且炎症标志物高的患者,托珠单抗机械通气风险增加。

核心结论

  • 在真实世界队列中,托珠单抗与利妥昔单抗在RA-ILD患者中显示出相当的有效性和安全性。
  • 对于基线炎症标志物升高的患者,利妥昔单抗可能比托珠单抗是更安全的选择。

研究设计与样本

  • 利用TriNetX美国协作网络数据库模拟目标试验,比较托珠单抗与利妥昔单抗治疗的RA-ILD患者。
  • 采用倾向评分匹配平衡组间疾病严重程度,匹配后每组各1194例患者。
  • 主要和次要结局包括全因死亡率和医疗资源利用风险,使用Cox回归估计风险比(HR)。
  • 进行了亚组和敏感性分析。

主要发现

  • 5年内,托珠单抗组与利妥昔单抗组的全因死亡率无显著差异(HR 1.073;95%CI 0.881-1.305)。
  • 次要结局包括住院和机械通气风险两组相当。
  • 排除其他系统性自身免疫性风湿病相关间质性肺病患者后,结果一致。
  • 在敏感性分析中,基线炎症标志物升高的RA-ILD患者使用托珠单抗的机械通气风险更高(HR 1.936;95%CI 1.125-3.331),全因死亡风险也更高(HR 1.403;95%CI 1.013-1.942)。
  • 此外,TNF抑制剂初治且炎症标志物高的患者使用托珠单抗的机械通气风险增加(HR 1.539;95%CI 1.074-2.206)。

临床怎么用

  • 在RA-ILD患者中,托珠单抗与利妥昔单抗总体疗效和安全性相当,可作为治疗选择。
  • 对于基线炎症标志物升高的RA-ILD患者,优先考虑利妥昔单抗可能更安全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) confers an increased risk of mortality among patients with RA. However, the optimal treatment strategies remain uncertain due to the limited high-quality evidence available. RESEARCH QUESTION: In patients with RA-ILD, how does tocilizumab compare with rituximab in terms of prognosis? STUDY DESIGN AND METHODS: This study used the TriNetX US Collaborative Network database to emulate a target trial of patients with RA-ILD treated with either tocilizumab or rituximab. Propensity score matching was used to balance disease severity between groups. Primary and secondary outcomes included all-cause mortality and medical utilizations risk. Hazard ratios (HRs) were estimated by using Cox regression. Subgroup and sensitivity analyses were performed. RESULTS: Each matched cohort included 1,194 patients. Over 5 years, all-cause mortality did not differ significantly between the tocilizumab and rituximab groups (HR, 1.073; 95% CI: 0.881-1.305). Secondary outcomes, including hospitalization and mechanical ventilation, were also comparable. Excluding patients with other systemic autoimmune rheumatic disease-related interstitial lung diseases yielded consistent results. In sensitivity analysis, patients with RA-ILD with elevated baseline inflammatory markers experienced higher risks with tocilizumab in mechanical ventilation (HR, 1.936; 95% CI, 1.125-3.331) and all-cause mortality (HR, 1.403; 95% CI: 1.013-1.942). In addition, patients naive to tumor necrosis factor inhibitor therapy with high inflammatory markers had an increased risk of mechanical ventilation (HR, 1.539; 95% CI, 1.074-2.206). INTERPRETATION: In this real-world cohort, tocilizumab and rituximab displayed comparable effectiveness and safety in RA-ILD. However, among patients with elevated baseline inflammatory markers, rituximab might be a safer choice than tocilizumab.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wu Z, Shih PC, Wang SI, et al. Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial. Chest. 2025. PMID: 40975268. doi:10.1016/j.chest.2025.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。